Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Precision BioSciences, Inc.

Precision BioSciences, Inc. (Nasdaq: DTIL) is a pre-clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Aliment Capital

The Longevity Fund

RA Capital Management

Leerink Partners

Ridgeback Capital

Alexandria Venture Investments

Cormorant Asset Management

Ditch Plains Capital Management LP

DUMAC

F-Prime Capital

Following pre-IND regulatory feedback from the FDA and ex-US regulators, we are advancing PBGENE-HBV toward an IND/CTA filing in 2024. 
 
The goal of our #investigational PBGENE-HBV program is to achieve a functional cure for patients with Chronic Hepatitis B. Hear from Chari Cohen, president of the Hepatitis B Foundation, on what this could mean for those living with HBV.
 
https://bit.ly/48fEVrt

How is ARCUS positioned to move beyond simple gene knockouts and tackle more sophisticated edits like gene elimination, excision, and insertion? 

Hear from Precision CRO, Jeff Smith in his #JPM2024 interview with pharmaphorum as they discuss the future of gene editing with ARCUS and going beyond CRISPR for in vivo gene editing.

Watch:
https://bit.ly/3TXFhQ4

Good news! We’ve completed a licensing deal with TG Therapeutics, Inc. to develop azer-cel for autoimmune diseases.

The deal extends our cash runway into the first half of 2026 and funds our wholly owned In vivo gene editing programs PBGENE-HBV for chronic hepatitis B and PBGENE-PMM for primary mitochondrial myopathy through Phase I Clinical Data.

Precision remains focused on capitalizing on the utility of ARCUS for gene elimination, gene excision and gene insertion through the advancement of our wholly owned and partnered programs.

Read more #JPM24: https://bit.ly/48IqY63

Precision CEO, Michael Amoroso, will speak at Longwood Healthcare Leaders in San Francisco on “The Future of Genetic Therapies” – joining other key industry thought leaders to discuss a wide range of issues affecting biopharma and healthcare. #longwoodhealthcareleaders

Learn more: https://bit.ly/3Tzx7gz

Precision’s Wendy Shoop, PhD., and University of Miami’s Carlos Moraes spoke with BioWorld about the recent publication in Nature Metabolism on mitoARCUS and our #investigational approach to primary mitochondrial myopathy. Read more from their conversation here: https://bit.ly/48g3Bk6

We’re pleased to announce the approval of the first clinical trial application of an ARCUS gene insertion program. Our partner iECURE received clearance from the Australian Therapeutic Goods Administration for a Phase 1/2 trial of ECUR-506, incorporating an ARCUS nuclease for the treatment of OTC deficiency. https://bit.ly/3NsrYDc

At this year’s Hep DART 2023, our Chief Research Officer and co-founder, Jeff Smith, & HBV Research Lead, Emily Harrison, presented on our #investigational PBGENE-HBV program. 

Learn more about our in vivo gene editing: https://bit.ly/41dIegX

We’re proud to share new research published in Nature Metabolism alongside Carlos Moraes that supports the development of mitoARCUS as an in vivo gene editing therapeutic for mitochondrial DNA diseases associated with the m.3243A>G mutation. Read more: https://bit.ly/3tcryK2.

In honor of #Thanksgiving tomorrow we want to thank all our employees for their dedication and celebrate our stakeholders for their investment and belief in Precision. It’s been an active year for us, and we’re looking forward to closing out the year strong.

We’re excited to share that we presented at the Sidoti & Company, LLC November Conference earlier today on our innovative ARCUS technology. ARCUS is capable of more sophisticated gene edits, with a focus on insertions, excisions and eliminations. That is the #ARCUS difference. See a recording of the presentation at the link below: https://bit.ly/3QZ4WWx

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-21.10M -	-46.04M 118.16%	-92.88M 101.74%	-109.01M 17.37%	-30.60M 71.93%	-111.64M 264.80%	-61.32M 45.07%
depreciation and amortization	1.44M -	2.35M 64.04%	5.32M 125.87%	9.81M 84.56%	10.20M 3.91%	9.00M 11.70%	8.26M 8.32%
deferred income tax			22K -		-6.14M -		-1.33M -
stock based compensation	419K -	2.45M 485.44%	8.94M 264.45%	13.79M 54.21%	16.51M 19.79%	19.20M 16.25%	14.04M 26.86%
change in working capital	-5.09M -	-10.51M 106.22%	-2.36M 77.57%	-2.01M 14.55%	19.58M 1,072.39%	24.11M 23.11%	1.33M 94.50%
accounts receivables		-523K -	-441K 15.68%	-9.04M 1,948.75%	9.51M 205.28%	-232K 102.44%	-181K 21.98%
inventory		-5.95M -	5.28M 188.85%	8.01M 51.68%	4.30M 46.27%
accounts payables	864K -	-673K 177.89%	667K 199.11%	-1.46M 318.14%	867K 159.59%	153K 82.35%	1.51M 885.62%
other working capital	-5.96M -	-3.37M 43.53%	-7.87M 133.76%	463K 105.89%	4.90M 958.32%	24.19M 393.65%	-1.33M 105.49%
other non cash items	174K -	14K 91.95%	9.94M 70,900%	35K 99.65%	-20.40M 58,394.29%	13.57M 166.52%	-46.42M 441.98%
net cash provided by operating activities	-24.17M -	-51.72M 114.01%	-71.02M 37.30%	-87.39M 23.05%	-10.85M 87.58%	-45.75M 321.57%	-84.11M 83.84%
investments in property plant and equipment	-5.57M -	-15.68M 181.73%	-24.67M 57.33%	-5.03M 79.60%	-5.80M 15.34%	-3.32M 42.81%	-1.96M 41.04%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites	50K -	15K 70%					7.79M -
net cash used for investing activites	-5.51M -	-15.66M 184.01%	-24.67M 57.48%	-5.03M 79.60%	-5.80M 15.34%	-3.32M 42.81%	5.83M 275.63%
debt repayment			-39.55M -		-2.50M -	-19.80M 692.20%
common stock issued			135.19M -	1.33M 99.02%	60.48M 4,450.56%	74.34M 22.93%	4.99M 93.29%
common stock repurchased	-952K -
dividends paid
other financing activites	15K -	107.78M 718,413.33%	77.74M 27.87%		12.54M -	40.45M 222.43%	401K 99.01%
net cash used provided by financing activities	-937K -	107.78M 11,602.35%	173.37M 60.86%	1.33M 99.23%	70.52M 5,206.32%	94.98M 34.69%	5.39M 94.33%
effect of forex changes on cash
net change in cash	-30.62M -	40.39M 231.91%	77.69M 92.35%	-91.09M 217.24%	53.87M 159.14%	45.91M 14.76%	-72.90M 258.77%
cash at beginning of period	93.42M -	62.80M 32.78%	103.19M 64.31%	180.89M 75.29%	89.80M 50.36%	143.66M 59.98%	189.58M 31.96%
cash at end of period	62.80M -	103.19M 64.31%	180.89M 75.29%	89.80M 50.36%	143.66M 59.98%	189.58M 31.96%	116.68M 38.45%
operating cash flow	-24.17M -	-51.72M 114.01%	-71.02M 37.30%	-87.39M 23.05%	-10.85M 87.58%	-45.75M 321.57%	-84.11M 83.84%
capital expenditure	-5.57M -	-15.68M 181.73%	-24.67M 57.33%	-5.03M 79.60%	-5.80M 15.34%	-3.32M 42.81%	-1.96M 41.04%
free cash flow	-29.73M -	-67.40M 126.68%	-95.68M 41.96%	-92.42M 3.41%	-16.66M 81.98%	-49.07M 194.62%	-86.07M 75.40%

COM:PRECISIONBIOSCIENCES

Precision BioSciences, Inc.

Last Close

5.15

07/03 21:00

Market Cap

67.46M

Beta: -

Volume Today

74.55K

Avg: -

Preview